Helsinn Healthcare S.A.

Helsinn Healthcare S.A. is a privately owned global pharmaceutical company headquartered in Lugano, Switzerland. Established in 1976 by Dr. Gabriele Braglia, it is a third-generation family-owned enterprise. The company's core mission is to champion and support patients with cancer and chronic diseases throughout their journey by providing effective medications and solutions. Helsinn focuses on improving the quality of life for patients, with a particular emphasis on supportive care, oncology, and dermato-oncology.

Helsinn builds, manufactures, launches, and commercializes a portfolio of pharmaceutical products. Key products include Akynzeo® and Aloxi® for chemotherapy-induced nausea and vomiting (CINV), Valchlor®/Ledaga® for cutaneous T-cell lymphoma, Adlumiz® for cancer cachexia (approved in Japan), and Arokaris® for CINV (approved in Japan). The company operates an integrated licensing business model and maintains manufacturing operations in Ireland, direct commercial operations in the U.S., and offices in China, facilitating a commercial presence in approximately 90 countries through a network of partners.

In January 2026, Helsinn announced a new Executive Leadership Team as it celebrated its 50th anniversary, with Riccardo Braglia returning as Chief Executive Officer. Gabriele Braglia serves as Chief Business Officer and Deputy CEO, alongside other key appointments. Recent strategic activities include expanding partnerships for Akynzeo® and Aloxi® in European markets and initiating a strategic collaboration with InVirtuoLabs for AI-driven drug discovery. The company continues to position itself as a global leader in supportive care for cancer and chronic diseases.